Skip to main content

Table 4 Clinical management of FN based on expert opinion

From: The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Drug name Patients treated among those developing FN (%)a Total daily dose (mg) Average duration (days)
Piperacillin + tazobactam 34% 16 000 6.1
Amikacin 26% 1 000 to 1 500 4.1
Ceftazidime 18% 2 625 to 4 000 5
Amoxycillin + clavulanic acid 17% 6 000 5.4
Cefepime 14% 6 000 to 16 000 5.8
Filgrastim 13% 0.3 4.5
Fluconazole 8% 200 to 400 6.5
Ciprofloxacin 7% 0.3 5.5
Procedure name Patients treated among those developing FN (%)* Average frequency of procedure
Chest X-ray 80% 1.2
Microbiological tests 78% 2.4
Abdominal echography 7% 1.0
Hospitalization by usage of PP/SP Patients hospitalized among those developing FN (%) Average [range] LOS (days)
No G-CSF prophylaxis 48% 4.2 [3-7]
PP 19% 1.5 [1-2]
SP 20% 3.3 [3-7]
  1. Only resources with frequencies >5% are reported. The table is based on oncologists' answers. The participating hematologists reported similar findings (results not shown).
  2. LOS: length of stay
  3. aObtained by multiplying the percentage of experts mentioning the drug/test by the average proportion of patients receiving this drug/test as estimated by these experts.